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Bifidobacterium longum subsp. infantis (B.
infantis) in healthy breastfed infants: study
protocol for a randomised controlled trial
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Abstract
Background: The development of probiotics as therapies to cure or prevent disease lags far behind that of other
investigational medications. Rigorously designed phase I clinical trials are nearly non-existent in the field of
probiotic research, which is a contributing factor to this disparity. As a consequence, how to appropriately dose
probiotics to study their efficacy is unknown. Herein we propose a novel phase I ascending dose trial of
Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut
colonisation in healthy breastfed infants at 6 weeks of age.
Methods/design: This is a parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I
clinical trial of dietary supplementation with B. infantis in healthy breastfed infants. The objective is to determine
the pharmacologically effective dose (ED) of B. infantis required to produce predominant (>50 %) gut colonisation
in breastfed infants at 6 weeks of age. Successively enrolled infant groups will be randomised to receive two doses
of either B. infantis or placebo on days 7 and 14 of life. Stool samples will be used to characterise the gut
microbiota at increasing doses of B. infantis.
Discussion: Probiotic supplementation has shown promising results for the treatment of a variety of ailments, but
evidence-based dosing regimes are currently lacking. The ultimate goal of this trial is to establish a recommended
starting dose of B. infantis for further efficacy-testing phase II trials designed to evaluate B. infantis for the
prevention of atopic dermatitis and food allergies in at-risk children.
Trial registration: Clinicaltrials.gov #NCT02286999, date of trial registration 23 October 2014.
Keywords: Bifidobacterium infantis, Probiotic, Atopy, Dose-escalation, Phase I clinical trial, Atopic dermatitis, Food
allergy
Background
The idea of probiotics, “live microorganisms that when
administered in adequate amounts confer a health bene-
fit on the host”, dates back to Elie Metchnikoff who
hypothesised over 100 years ago that lactic acid bacilli
had health benefits [1]. To date, thousands of reports of
probiotics have supported the potential health benefits
of these bacteria and the World Health Organization
(WHO) has formulated guidelines for their use as nutri-
tional supplements as well as investigation into their po-
tential therapeutic properties [2]. Probiotics have been
studied for the treatment and prevention of a variety of
diseases in children including atopic dermatitis, bacterial
gastroenteritis, inflammatory bowel disease, and necro-
tizing enterocolitis [3–5]. Overall, the data concerning
probiotics as preventive agents for atopic diseases such
as atopic dermatitis and food allergies are inconclusive,
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with some studies suggesting a possible benefit and
others showing mixed results [4, 6–8].
Humans and other mammals are hosts to a diverse
set of symbiotic as well as pathogenic intestinal bac-
teria. Approximately 1000 microbial species reside at a
density of 1 × 1012 organisms per gram of colonic con-
tent [9, 10]. Several studies have demonstrated a clear
link between immune system development and the
composition of gut microbiota [11–13]. In addition,
disruption of intestinal barrier function may lead to
premature exposure of the infant to atopy-inducing
environmental allergens, which would theoretically
predispose the infant to the development of food aller-
gies [14]. By protecting against colonisation by patho-
genic bacteria, probiotics may help protect intestinal
barrier function and thus decrease the susceptibility
for development of atopic diseases and food allergies
[15]. However, the pharmacokinetics of commensal
bacteria and the dosage required to achieve predomin-
ant gut colonisation has thus far not been quantified.
The probiotic that will be administered in our pro-
posed phase I clinical trial, Bifidobacterium longum
subsp. infantis (B. infantis), is unique in that it is able
to fully utilise human milk oligosaccharides [16]. Thus,
an exclusively breastfed infant’s gut provides the ideal
environment to facilitate colonisation with this com-
mensal bacteria [16–18].
In order to proceed with designing a rigorous phase
II clinical trial program to evaluate B. infantis as a pre-
ventative measure for a variety of childhood ailments,
including atopic disease, it is necessary to first deter-
mine the pharmacologically effective dose (ED) of B.
infantis. To date, pharmacologically guided phase I
studies have not been conducted in the field of probio-
tics. We are thus proposing a phase I dose-escalation
trial to evaluate the safety and pharmacokinetics of B.
infantis supplementation when administered to healthy
breastfed infants. The primary endpoint of the pro-
posed trial is identification of the ED of B. infantis, de-
fined as the dose required to produce predominant
(>50 %) gastrointestinal colonisation in breastfed in-
fants by 6 weeks of age. The 50 % value was chosen
based on the proportion of B. infantis colonisation ob-
served in breastfed infants in less-developed countries
that have a low incidence of atopic disease compared to
infants in the United States, specifically that seen in
Bangladeshi infants [19, 20].
If successful, this study will be the first of its kind to
establish a standardised dosing regime for probiotic sup-
plementation in infants and will serve as a platform from
which to design phase II and III trials to investigate the
ability of B. infantis to protect against the development
of a variety of childhood illnesses, including atopic
dermatitis and food allergies.
Methods/Design
Study design
The proposed phase I clinical trial is a parallel-group,
placebo-controlled, randomised, double-blind ascending
dose study of dietary supplementation with B. infantis in
healthy breastfed infants to evaluate its safety as well as
determine the ED of B. infantis producing >50 % gut
colonisation at 6 weeks of age. Infants will be enrolled
sequentially in groups of five (three randomised to re-
ceive B. infantis and two to receive placebo). The trial
participants and investigators will be blinded as to their
group randomisation, which will be conducted by the
study pharmacist (who will then dispense blinded B.
infantis or placebo to the investigators). Depending on
group assignment, each infant will receive one dose of
either B. infantis or placebo on day 7 and another on
day 14 of life (two doses total). For infants in the B.
infantis group, a calculated maximally recommended
starting dose (MRSD) will be used to initiate the dose
escalation and is defined below. Every 2 weeks, an add-
itional group of five infants (randomised 3:2 to B. infan-
tis and placebo) will be enrolled to receive progressively
higher doses of B. infantis. Calculation of the appropri-
ate dose escalation will be performed using a modified
Fibonacci series as described below in an effort to iden-
tify the ED of B. infantis.
After the ED of B. infantis has been identified (defined
as the dose capable of producing 50 % gut colonisation
by 6 weeks of age) two additional sequential dose escala-
tions will be performed. The purpose of the final two
dose escalations is to determine if successively higher
doses of B. infantis result in increased gut colonisation
or barrier protection, or, alternatively, if a maximum ef-
fective dose (MaxED) for B. infantis exists above which
there is no further increase in gut colonisation or barrier
protection. Following the final dose escalation, Hanley’s
Rule of Three will be applied in order to determine if
lower-frequency adverse events are caused by B. infantis.
Hanley’s Rule of Three states that in order to identify any
adverse events occurring at a frequency of 1:10 or greater
with a 95 % confidence interval, at least 30 subjects must
be enrolled [21]. A schematic overview of the trial design
and dose escalation protocol is provided in Fig. 1.
Study visits will be scheduled for weeks 1, 2, 6, 24, 36,
52, and 78. Parents will complete surveys at each study
visit to monitor the infants for potential adverse events
associated with probiotic administration including feed-
ing intolerance, fevers, or bowel irregularities including
constipation and diarrhoea.
Stool samples will be collected twice weekly for the
first 6 weeks of life then once weekly at weeks 24, 36,
52, and 78. Stool samples will be analysed to determine
the relative abundance of B. infantis over time, and the
overall diversity of the gut microbiota with and without
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B. infantis supplementation. Stools will also be analysed
for milk oligosaccharides to verify consumption of breast
milk and to correlate the proportion of human milk oli-
gosaccharides and free sugar monomers seen in the in-
fant stool at various levels of B. infantis colonisation.
Breast milk will be collected at 7, 14, 42, 120, and
180 days after the birth of the infant to determine the type
and proportion of milk oligosaccharides present at various
time points. The purpose of this analysis is to allow correl-
ation of the type and amount of milk glycans present in
breast milk with that in the infant stool samples.
Entry into the study requires the intent to breastfeed
exclusively for a minimum of 6 months. If mothers de-
cide to discontinue breastfeeding during the study, we
will note that in the infant’s notes and obtain an add-
itional series of weekly stool samples for 6 weeks after
discontinuation of breastfeeding. The purpose of this
additional stool sample collection is to determine if dis-
continuation of breastfeeding has an impact on the level
of existing B. infantis colonisation in the infant gut.
A table of the schedule of study visits and specimen
collections is provided in Table 1, and an overview of
the timeline of the study interventions and assessments
is provided in Table 2.
Patient recruitment
As infants need to be enrolled within the first week of
life, efforts will target pregnant women. Institutional
Review Board (IRB)-approved flyers will be used to
recruit pregnant women to participate in the study
from the UC Davis Family Practice Center, UC Davis
Obstetrics & Gynecology offices, and the inpatient
Labor and Delivery ward.
Informed consent process
During the initial screening visit, written informed con-
sent will be obtained from the mother for infant partici-
pation in the study. The parents will be instructed on
the proper collection and home storage of infant stool
and maternal breast milk samples.
The potential risks and benefits to enrolled infants
are outlined below in lay terms, as described in the
IRB-approved consent forms that will be used to con-
sent the parents/guardians of eligible infants for study
participation:
“Probiotics are living organisms such as bacteria or
yeast that are sold as dietary supplements for the pur-
pose of improving health. Probiotics may have benefits
such as decreasing the growth of harmful bacteria in the
gastrointestinal tract, improving digestion and helping to
strengthen the immune system. Probiotics have shown
some benefit in reducing the risk of developing atopic
(allergic) dermatitis in children. However, this optimal
dose of probiotic needed to achieve such beneficial ef-
fects has not yet been studied in randomised controlled
clinical trials. We wish to investigate the optimal dose
of probiotic bacteria needed to colonise the infant
gastrointestinal tracts by 6 weeks of age. We will also
Fig. 1 A parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I study of dietary supplementation with B. infantis.
Groups of healthy infants will receive increasing doses of B. infantis until it comprises 50 % of their gut microbiota, defined as the pharmacologically
effective dose (ED). This figure arbitrarily designates Group 6 as receiving the ED of B. infantis. After the ED has been reached, two additional dose
escalations will occur to determine the impact that additional B. infantis has on the gut microbiota. To satisfy Hanley’s Rule of Three, 30 infants will
receive the highest dose of B. infantis. “X” represents the maximum recommended starting dose (MRSD). A modified Fibonacci Series (X, 2X, 3X, …) is
used to guide the dose escalations. CFU colony-forming units
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monitor patients for any evidence of atopic dermatitis
(AD) and any effect on the severity of the AD during
the course of the study.
Side effects described with probiotic use include diar-
rhea, vomiting and increased flatulence. Serious adverse
effects of probiotics in infants include an extremely low
risk of systemic infection (bacteraemia), but have thus
far only been reported in children who were immuno-
compromised. Only healthy infants without any major
systemic illnesses will be eligible to participate in this
study, so we anticipate very minimal physical risks to
subjects under these conditions.
However, as a result of being in the study your infant
may experience one or more of the following adverse
side effects listed below:
 Fever greater than 102°Farenheit
 Feeding difficulties (decreased feeding, colic,
spitting up)
 Irregular bowel movements (diarrhea or
constipation)
 Blood or pus in the stool
 Vomiting
 Abdominal pain or swelling
Table 1 Schedule of study visits and specimen collections for each infant and mother
Week Visits and activities
Prior to starting the study • The patients’ parents or legal guardians will be asked to read and sign the consent form
and will be instructed on the procedures for collection and storage of stool samples. They
will be asked to refrain from giving the child any other dietary supplementation or probiotics
while in the study and to inform the researchers if they are prescribed oral antibiotics at
any time during the study.
Week 1 • Initial study visit, adverse event survey administration to parents and administration of
first dose of B. infantis or placebo on day 7 of life.
• Week 1 stool samples collected (infants will have stool samples collected twice weekly
for the first 6 weeks and then at the study visits at weeks 6, 24, 36, 52, and 78).
• If breastfeeding is discontinued at any point in the study, an additional series of six weekly
stool samples will be collected following discontinuation in addition to the regularly
scheduled collections
• Mother collects breast milk on day 7 of life.
Week 2 • Study visit, adverse event survey administration to parents and administration of second
dose of B. infantis or placebo on day 14 of life.
• Week 2 stool samples collected
• Mother collects breast milk on day 14 of life.
Week 3 • Week 3 stool samples collected
• Adverse event survey administration to parents
Week 4 • Week 4 stool samples collected
• Adverse event survey administration to parents
Week 5 • Week 5 stool samples collected
Week 6 • Study visit, adverse event survey administration to parents.
• Week 6 stool sample collected.
• Mother collects breast milk on day 42 of life.
Week 17 • Mother collects breast milk on day 120 of life.
Week 24 • Study visit, adverse event survey administration to parents.
• Week 24 stool sample collected.
Week 25 • Mother collects breast milk on day 180 of life.
Week 36 • Study visit, adverse event survey administration to parents.
• Week 36 stool sample collected.
Week 52 • Study visit, adverse event survey administration to parents.
• Week 52 stool sample collected.
Week 78 • Study visit, adverse event survey administration to parents.
• Week 78 stool sample collected.
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Table 2 Schedules for study participant enrolment, interventions and assessments in parallel-group, placebo-controlled, randomised, double-blind ascending dose phase I study
of dietary supplementation with B. infantis
Enrolment Allocation Post-allocation
Timepoint –t1 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 17 Week 24 Week 25 Week 36 Week 52 Week 78
Enrolment:
Eligibility screen X
Informed consent X
Allocation X
Interventions:
Dose #1 of B. infantis/placebo X
Dose #2 of B. infantis/placebo X
Infant stool collection X X X X X X X X X X
Breast milk collection X
(Day 7
of life)
X
(Day 14
of life)
X
(Day 42
of life)
X
(Day 120
of life)
X
(Day 180
of life)
Assessments:
Identification of pharmacologically
effective dose (ED) of B. infantis
X
Study visit X X X X X X X
Adverse event survey X X X X X X X
Analysis of stool oligosaccharides X X X X X X X X X X
Analysis of stool microbiota X X X X X X X X X X
Analysis of breast milk
oligosaccharides
X
(Day 7
of life)
X
(Day 14
of life)
X
(Day 42
of life)
X
(Day 120
of life)
X
(Day 180
of life)
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 Sepsis (serious infection involving the presence of
bacteria in the baby’s blood)”
Study inclusion and exclusion criteria
Inclusion criteria
 Healthy newborn infants between 1 and 7 days old
with intent to be exclusively breastfed for a
minimum of 6 months
Exclusion criteria
 Infants given dietary supplementation, including
other probiotics.
 Infants born prior to 34 weeks gestation.
 Infants below 10th percentile for body weight.
 Postnatal use of antibiotics (oral, intramuscular, or
intravenous) by either the mother or the infant. Of
note, prenatal maternal Group B streptococcus
prophylaxis is not a criterion for study exclusion.
 Family history of immunodeficiency syndrome(s).
 Infants with signs of a clinically apparent underlying
immunodeficiency.
 Intent to use non-breast milk infant formula for
feeding during the first 6 months.
 History of gastrointestinal tract abnormality or
infection.
Protocol for calculating the starting dose of B. infantis
and dose escalation
Previous studies of B. infantis supplementation in pre-
mature infants at the UC Davis neonatal intensive care
unit (NICU) have used a dose of 1.4 × 109 colony-
forming units twice daily for 2 weeks without any ob-
served serious adverse effects [22]. Applying a safety fac-
tor of three and adjusting for once-daily dosing yields, a
MSRD of 0.9 × 109 colony-forming units of B. infantis is
to be administered on day 7 and day 14 of life. Each
group of five infants will be enrolled at least 2 weeks
apart to allow for sufficient time to identify possible ad-
verse events prior to each dose increase. A modified
Fibonacci-based dose escalation protocol will be applied
as shown below:
Fn ¼
Xn−12½ 
k¼0
n−k−1
k
 
The specific modified-Fibonacci series will be as
follows:
×, 2×, 3×, 5×, 9×, 12×, and 16× (where × = 0.9 × 109
colony-forming units of B. infantis)
Based on the schedule for enrolling new groups every
2 weeks, by the time the pharmacologically effective
dose (ED, defined as the dose of B. infantis resulting in
50 % gut colonisation at 6 weeks of age) has been identi-
fied, two additional dose escalations will have been per-
formed in successive infant groups. Figure 1 provides
schematic representation of infant group enrollment as
well as the dose escalation protocol to identify the ED
for B. infantis as well as the MaxED, if applicable.
Study-wide number of subjects
We propose a maximum sample size of 90 infants. Five
infants (three to receive B. infantis supplementation and
two to receive placebo) will be enrolled for the initial
dose of B. infantis. An additional five infants will be en-
rolled at each dose escalation. Once the pharmacologic-
ally effective dose (ED) of B. infantis has been reached,
two additional dose escalations will be performed (for
reasons as described above). We estimate that the ED of
B. infantis will be identified within seven dose escala-
tions (35 infants). Accounting for the final two dose es-
calations will bring the total to 45 infants. Following the
final dose escalation, 45 additional infants (27 to receive
B. infantis and 18 to receive placebo) will be enrolled to
screen for lower-frequency adverse events using Hanley’s
Rule of Three [21]. This will bring the maximum enroll-
ment number to 90 infants. If the ED of B. infantis re-
quired to produce 50 % gut colonisation at 6 weeks is
not reached, then enrollment will be halted after 90 in-
fants have been enrolled. Additional stopping rules are
listed in the “Study Endpoints” section.
Randomisation
A computer-generated list of random numbers will be
used to create a series of numbered, sealed opaque enve-
lopes containing assignments to either placebo or sup-
plementation with B. infantis. For every three infants
assigned to B. infantis supplementation, two additional
infants will be assigned to placebo. The study pharmacist
will be responsible for the randomisation and delivery of
the blinded supplements.
Study methods and interventions
Infant stool collection
Parents will be instructed how to collect and store infant
stool samples at home. Stool samples will be collected
twice weekly for the first 6 weeks of life then once
weekly at weeks 24, 36, 52, and 78. If breastfeeding is
discontinued at any point, an additional series of weekly
stool samples will be collected for 6 weeks following dis-
continuation. At the initial enrollment visit parents will
be provided with a stool sample collection including a
sealable freezer box, marked sealed collection tubes and
sealable plastic bags. Parents will be instructed to store
samples in their home freezers immediately after collec-
tion to prevent secondary bacterial growth, and discard
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any samples not able to be frozen at the time of collec-
tion. Stool samples will be stored in the home freezers of
study participants and picked up by study personnel
once weekly to ensure they can be properly transported
to the laboratory under temperature-controlled condi-
tions. Any samples that are not stored immediately in
the freezer at the time of collection or thaw en route to
the laboratory will be discarded and parents will be
instructed to collect and store a new stool sample ac-
cording to the protocol. The stool samples will be ana-
lysed in the laboratory using DNA extraction to
determine the identity and predominance of various
commensal bacterial species, including the percentage of
B. infantis present. The method of stool collection that
will be provided to parents is described below:
1. At any time of day, scoop 1–2 teaspoons of your
infant’s stool with the tongue depressor into the
sealable collection tube. The amount of stool should
fill the tube between the 5 and 10 ml mark.
2. Seal the tube and label with the time and date it was
collected.
3. Place the stool filled tube inside a sealable plastic
bag and seal it.
4. IMMEDIATELY place the sealed bag containing the
stool sample into the study freezer box and store it
in your freezer. It is important that stool samples
are stored in the freezer immediately after
collection to prevent bacteria from growing. If the
stool sample was not immediately placed in the
freezer, please discard the sample and collect
another sample from your baby at the earliest
convenience.
Breast milk collections
Mothers will collect a series of breast milk samples for
laboratory analysis to determine the type and proportion
of milk oligosaccharides present at various time points.
The purpose of this analysis is to allow correlation of the
type and amount of milk glycans present in breast milk
with that in the infant stool samples, both to verify the
presence of the specific oligosaccharides preferred by B.
infantis as well as to determine if appropriate amounts
are present in the infant stool to represent exclusive
breastfeeding practices.
Breast milk will be collected at 7, 14, 42, 120, and
180 days after the birth of the infant, and stored in the
home freezers in the same manner as the stool samples.
Parents will be provided with detailed instructions and
supplies for collection as described below:
1. Between 2–4 hours after your last breastfeeding, use
the breast pump to pump all the milk from one
breast into the breast pump collection bottle.
2. Using the measuring cup, measure out 12 ounces of
breast milk.
3. Divide the 12 ounces of breast milk into three (3)
collection tubes, with four (4) ounces per tube.
4. Using the collection tube labels and a permanent
marker, label each collection tube with the date and
time of collection.
5. IMMEDIATELY, place the three tubes of breast milk
in a single ziplock bag, seal it, and place in the study
collection box stored in your freezer.
6. Wash and dry the breast pump, collection bottle,
and measuring cup thoroughly after each use
Data management and specimen banking
Collected breast milk and stool samples will be labelled
with a four digit number randomly assigned to each pa-
tient as well as the date of sample collection. De-identified
samples will be delivered to the laboratory for processing.
Precautions will be taken to maintain the privacy of all
participants. Personal information maintained on infant
subjects will include age, first initial, last name, and four
digit medical record number assigned at the time of ran-
domisation. Patient information will not be disclosed to
third party individuals except those authorised to oversee
the research project.
Study endpoints
Primary outcome measures
Identification of pharmacologically effective dose (ED) of B.
infantis
The primary endpoint of the study is identification of
the ED of B. infantis, i.e. the dose required to produce
predominant (>50 %) gut colonisation at 6 weeks of age.
The value of 50 % colonisation was chosen because B.
infantis represented greater than 50 % of the gut micro-
biota in the vast majority of Bangladesh infants [19].
The percent gut colonisation will be determined through
analysis of stool samples by 16S sequencing.
Safety
An additional primary endpoint is to determine the safety
of B. infantis supplementation in immunocompetent, full-
term infants. Any adverse events including fever of 38.9 °C
(102 °F) or higher, abdominal pain or colic, blood or puru-
lence in the stool, diarrhoea or vomiting will be docu-
mented and dosing adjusted accordingly (“Stopping rules”
are defined below).
Secondary outcome measures
Milk oligosaccharide consumption
All stool samples will also be analyzed for the presence
of oligosaccharides unique to breast milk and for the
presence of free saccharide monomers, which are
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products of their incomplete digestion. B. infantis abun-
dance will be correlated to these values.
Microbiota composition
In addition to determining the percent composition of
B. infantis in infant stool samples, numerous other mea-
sures such as microbiota diversity (Shannon Diversity
plots) and rate of B. infantis decline following cessation
of breast feeding will also be determined.
Provisions to monitor data and ensure safety of subjects
Children will be recruited for this study. Subjects will be
monitored clinically during the study period to assess
for potential adverse events. A previous study of B.
infantis supplementation in premature infants adminis-
tered similar doses and was well tolerated with no severe
adverse events noted [22]. Nonetheless, patients enrolled
in the study will be monitored closely and any evidence
of feeding intolerance, illness, or infection will be thor-
oughly evaluated. A survey to assess for any baseline
feeding intolerance or symptoms will be administered to
all infants prior to administration of B. infantis or pla-
cebo. Additional symptom questionnaires will be admin-
istered weekly during the first month of the study and at
every study visit therafter at 6, 24, 36, 52, and 78 weeks.
Patients will be provided with the contact information
for the principal investigator and on-call dermatology resi-
dent should any unforeseen symptoms or problems arise.
Rules for stopping dose escalation and halting trial
1) Dose escalation will be stopped if a maximally
tolerated dose (MTD) of B. infantis is reached. The
data safety monitoring board will evaluate the
adverse events reported at each ascending dose of B.
infantis. If the safety monitoring board deems that
one or more of the three infants in the B. infantis
supplementation group experienced an adverse
event (such as fever >38.9 °C (102 °F), abdominal
pain or colic, blood or purulence in the stool,
diarrhoea or vomiting) then additional dose
escalation will be halted.
2) In the event dose escalation is halted due to adverse
events, an additional group of five infants will be
enrolled with three infants at the same (i.e. not
escalated) dose of B. infantis and two receiving placebo.
3) If no adverse events occur in this additional, non-
escalated group, then dose escalation will be resumed
beginning with the next group of enrolled infants.
4) However, if adverse events are noted in one or more
infant(s) in the non-escalated group, all further dose
escalation will be halted. The B. infantis dose will be
de-escalated to the previous value, and an additional
group of five infants (three B. infantis, two placebo)
will be enrolled. If no adverse events occur in the
de-escalated group, this dose will be considered the
MTD and the trial will be stopped.
5) If any adverse events are noted in the de-escalated
group, further de-escalation and enrollment of
infants will occur to identify the dose of B. infantis
considered to be the MTD, in which no adverse
events occur in the study group.
Withdrawal of subjects
Subjects may be withdrawn without their consent if they
acquire medical issues during the study period that re-
quire administration of oral or parenteral antibiotics or
immunosuppressive medications. If a subject is to be
withdrawn, the parent(s) will be contacted and the rea-
son(s) for withdrawal will be explained in full. No fur-
ther data will be collected from withdrawn subjects.
Subjects have the right to withdraw from the study at
any time for any reason. Every effort will be made to
follow-up subjects who discontinue placebo or B. infan-
tis supplementation prior to the second dose. These
evaluations should continue according to the protocol of
scheduled study visits if at all possible. The reasons for
discontinuation will be recorded in the subjects’ study
file. If a subject is unable to return for evaluation, every
effort will be made to contact via telephone 28 days after
withdrawal to determine if any serious adverse events
have occurred while off study. Any identified adverse
events will be followed until resolution.
The investigator also has the right to remove subjects
from the study without their consent. Possible reasons
for removal include:
 Non-compliance with the study protocol
 Significant protocol deviation
 Serious adverse event potentially related to study
treatment
Subjects that withdraw after the 6 week study visit will
not be replaced with new subjects.
Discussion
From our experience of administering B. infantis to in-
fants in the NICU at UC Davis, it is highly unlikely that
a phase I trial will successfully identify a MTD of this
probiotic. Thus, our proposed phase I ascending dose
study will instead utilise a targeted outcome, optimal gut
colonisation of B. infantis at 6 weeks of age. Such “con-
centration controlled” phase I clinical trials that use
pharmacokinetics in place of drug toxicity to guide dose
escalation are supported in the literature [23, 24]. For
example, in molecularly targeted anticancer agents, tox-
icity concerns are reduced, making “drug-related bio-
logical effects” a better suited primary endpoint [25–28].
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Our specific trial will measure gut microbiota compos-
ition following B. infantis administration to determine
the dose of B. infantis that is required to successfully
colonise the gastrointestinal tract of a 6-week-old breast-
fed infant. Secondary outcome measures will include
measurement of complex glycan consumption by the in-
fant as well as diversity of the intestinal microbiota. As
in all phase I studies, the infants will be monitored
closely for adverse events. The main goal of this phase I
trial is to establish a recommended administering dose
of B. infantis to support further efficacy testing in phase
II and phase III trials.
Prior probiotic studies have differed from the proposed
study with regards to their dosing regime, inclusion cri-
teria, and types of bacteria administered. Many prior tri-
als in infants were designed with limited knowledge of
the human milk glycome and resultant effects on the in-
fant’s intestinal microbiotia. Probiotic bacteria used in
prior trials in children have included Bifidobacterium
breve, Bifidobacterium lactis, Bifidobacterium longum,
Lactobacillus acidophilus, Lactobacillus fermentum, and
Propinobacterium freudenreichii, among others [29–34].
In many prior studies, it was unclear why a particular
probiotic was chosen. Research done by the milk group
at UC Davis has shown that the vast majority of pro-
biotic species do not grow on the human milk oligosac-
charides in breast milk [16, 35, 36]. Evidently, most
probiotics studied in previous clinical trials have been
selected based on culturability and taste profiles when
administered as fermented food products rather than
their biological activity. In contrast, our proposed study
is based upon research into the human milk glycome
and insight into the specific bacteria that digest breast
milk oligosaccharides.
One unique aspect of this trial is that we will ad-
minister B. infantis to exclusively breastfed infants.
The breast milk will provide the prebiotic oligosac-
charides and thus select for the growth of B. infantis
over other gastrointestinal commensal bacteria. In
addition, we will monitor the composition of the in-
testinal microbiota should the mothers choose to dis-
continue breastfeeding to determine the effect breast
milk consumption has on the maintenance of B.
infantis intestinal colonisation. Previous studies inves-
tigating probiotics have administered the bacteria in
combination with galacto- and fructo-oligosaccharides
[37, 38]. However, these sugars differ significantly
from milk oligosaccharides in that they are linear ra-
ther than branched and lack fucose and sialic acid
moieties [39]. As human breast milk will comprise
the majority of an infant’s diet, supplementing with a
probiotic that thrives on human milk oligosaccharides
may be the most sensible strategy for cultivating a
protective microbiota in healthy infants.
The most common adverse effects described with pro-
biotic use include diarrhoea, vomiting, and increased
flatulence. Probiotics are known to be extremely safe, as
evidenced by prior use in premature infants as well as in
both adults and children with HIV [40, 41]. In Finland,
the use of probiotic supplements (namely Lactobacillus
rhamnosous GG) has increased dramatically over the
past 20 years without evidence of a corresponding in-
crease in the rate of lactobacillus bactermia [42, 43].
Probiotic supplementation has also been shown to be
well tolerated without adverse effects in a recent rando-
mised, double-blind, placebo-controlled trial comparing
a combination of lactobacilli (Lactobacillus salivarius
and Lactobacillus paracasei) and bifidobacteria (Bifido-
bacterium animalis subsp. lactis and Bifidobacterium
bifidum) in pregnant women and infants, with the goal
of assessing the safety of probiotic supplementation [44].
In this trial, enrolled women were treated with a total of
1 × 109 colony-forming units of this probiotic regime
daily for the last month of pregnancy and the regime
was then administered to their infants from birth
through to 6 months of age. There was no significant
difference in the incidence of adverse events in either
the maternal or infant groups, and no adverse events
were attributed directly to the probiotic supplementa-
tion. There have been rare reports demonstrating the
possibility of probiotic-related infectious complications,
such as sepsis, bacteraemia, and endocarditis [45–47].
However, it is estimated that the risk of developing bac-
teraemia from ingested Lactobacillus probiotics is less
than one in one million [48]. Though extremely rare, sep-
sis due to bifidobacterium has been described [49–51].
The described cases of bifidobacterium bacteraemia in-
clude one adult that developed incidental sepsis following
acupuncture, and two infants that received Bifidobacter-
ium breve or Bifidobacterium longum as a probiotic sup-
plement. Of note, one infant was premature with
extremely low birthweight and the other was full term
with comorbid omphalocele. To date there are no re-
ported instances of bacteraemia resulting from B. infantis;
however, all study participants will be warned of the ex-
tremely low risk of such complications.
While studies have demonstrated the ability of certain
probiotics to prevent childhood illnesses [8], there are
virtually no data on how to appropriately dose these
supplements. The typical probiotic study has adopted a
daily dosing regime, making feasibility an issue. Some-
times the probiotic is administered to the mother first
and then to the infant for the first 6 months of life.
Dose-ranging studies are usually required early on dur-
ing a drug’s clinical development. Excluding a few excep-
tions, probiotic dose-ranging studies are for the most
part non-existent [52–54]. As a follow-up clinical trial,
we plan to conduct a dose-ranging phase II study that
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will compare the effectiveness of B. infantis daily dosing
to a limited dosing regime consisting of B. infantis ad-
ministered on days 7 and 14 only. In theory, the human
breast milk oligosaccharides will bestow B. infantis with
a competitive growth advantage, making daily dosing
unnecessary. If the limited dosing regime is successful, it
will have an immediate health care impact, as inoculat-
ing breast fed infants with two doses of B. infantis is an
extremely feasible preventative measure to reduce the
incidence of atopy and other diseases in at-risk children.
The pharmacokinetically guided design of this pro-
posed phase I trial has not been attempted in prior pro-
biotic studies. If successful the trial will identify a
pharmacologically effective dose (ED) and maximum ef-
fective dose (MaxED) for B. infantis supplementation in
healthy infants. The next generation sequencing strategy
that will be employed to analyse the stool of the infants
to determine gut colonisation with B. infantis has been
well standardised, and is a common method for analysis
of gut microbiota. Infants will also be monitored closely
for potential adverse effects in case a maximally toler-
ated dose (MTD) is reached during the ascending dose
study. The design of the trial is also innovative because
the specific probiotic used for the supplementation will
have a competitive advantage in an exclusively breastfed
infant; it is the only bacterium that can fully utilise the
complex oligosaccharides in breast milk as an energy
source. Thus, the design of the trial provides an optimal
environment for B. infantis to outcompete other intes-
tinal microbiota. The rationale for the choice of pro-
biotic used in prior infant trials is not clear; however, in
this study it is based upon knowledge of the human milk
glycome and specific metabolic needs of B. infantis. Our
ultimate goal is to develop a clinically appropriate, safe,
and effective dosing regime for probiotics that may be
utilised in further phase II and phase III clinical trials. In
doing so, we hope to lay the foundation for the design of
objective, standardised clinical trials to assess the effi-
cacy of probiotics for the prevention of a variety of dis-
eases, including atopic dermatitis and food allergies in
at-risk infants.
Trial status
This protocol is for a proposed clinical trial. The phase I
protocol has been reviewed and approved by the UC Davis
Institutional Review Board (IRB). This trial has been regis-
tered through clinicaltrials.gov on 23 October 2014 and is
accessible online (Identification Number NCT02286999).
Patient recruitment has not yet commenced for this trial.
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